Fleboton Solution for injection

Composition

3 ml of solution for injection containing 150 mg Troxerutin and 1.5mg Carbazochrome.

Properties

Troxerutin (3-hydroxyethyl-rutoside), also known as vitamin P4, is a bioflavonoid that acts by increasing vasal resistance (capillary protective action) and diminishing permeability, thus preventing the excessive leakage of the liquid component of blood to tissues (anti- permeabilizing and anti- edemigenic action). 

Carbazochrome (adrenochrome semicarbazone), an ortho quinoline derived from adrenalin through oxidation and lateral chain cycling, is totally devoid of sympathomimetic action, owing to the absence of the secondary amine function and the ortho-diphenolic grouping, and it shortens the haemorrhage time through a local vasoconstrictive action on small vessels in the bleeding area. 

فليبوتون أمبولات
فليبوتون أمبولات

Therapeutic Indications

Symptomatic venous insufficiency; states of capillary fragility in post – hemorrhoidectomy patients.

Posology and method of administration

1 to 3 ampoules a day by intramuscular injection. The content of the ampoules must not be mixed with solutions containing ascorbic acid.

Contraindications

Hypersensitivity to the active substances or to any of the excipients. 

Special warnings and precautions for use

None.

Interactions with other medicinal products

None reported.

Pregnancy and lactation

For Fleboton  no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/ foetal development, parturition or postnatal development. 

Caution should be exercised when prescribing to pregnant women.

Effects on ability to drive and use machines

Fleboton has no influence on the ability to drive and use machines. 

Undesirable effects

Some cases of local and generalised erythema have been reported in patients receiving Fleboton solution for injection via the intradermal or subcutaneous route (mesotherapy).

The use of Fleboton solution or injection in mesotherapy is not approved since there are no controlled clinical studies showing the efficacy and safety of these methods of adminstration.

Overdose

No case of overdose has been reported.

ENG - Patient Information Leaflet
FLEBOTON – Patient Information Leaflet

Incompatibilities

Fleboton solution for injection should not be mixed with ascorbic acid.

أضف تعليقك

لن يتم نشر عنوان بريدك الإلكتروني.